Standard
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. / Muscelli, Elza; Casolaro, Arturo; Gastaldelli, Amalia; Mari, Andrea; Seghieri, Giuseppe; Astiarraga, Brenno; Chen, Yu; Alba, Maria; Holst, Jens Juul; Ferrannini, Ele.
In:
Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 8, 08.2012, p. 2818-26.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Muscelli, E, Casolaro, A, Gastaldelli, A, Mari, A, Seghieri, G, Astiarraga, B, Chen, Y, Alba, M
, Holst, JJ & Ferrannini, E 2012, '
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes',
Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 8, pp. 2818-26.
https://doi.org/10.1210/jc.2012-1205
APA
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M.
, Holst, J. J., & Ferrannini, E. (2012).
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Journal of Clinical Endocrinology and Metabolism,
97(8), 2818-26.
https://doi.org/10.1210/jc.2012-1205
Vancouver
Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B et al.
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Journal of Clinical Endocrinology and Metabolism. 2012 Aug;97(8):2818-26.
https://doi.org/10.1210/jc.2012-1205
Author
Muscelli, Elza ; Casolaro, Arturo ; Gastaldelli, Amalia ; Mari, Andrea ; Seghieri, Giuseppe ; Astiarraga, Brenno ; Chen, Yu ; Alba, Maria ; Holst, Jens Juul ; Ferrannini, Ele. / Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. In: Journal of Clinical Endocrinology and Metabolism. 2012 ; Vol. 97, No. 8. pp. 2818-26.
Bibtex
@article{21a5a06be11e49d882de35936916db36,
title = "Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes",
abstract = "Dipeptidyl peptidase IV (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes. The underlying mechanisms (incretin effect, β-cell function, endogenous glucose production) are not well known.",
keywords = "Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Insulin-Secreting Cells, Male, Middle Aged, Pyrazines, Triazoles",
author = "Elza Muscelli and Arturo Casolaro and Amalia Gastaldelli and Andrea Mari and Giuseppe Seghieri and Brenno Astiarraga and Yu Chen and Maria Alba and Holst, {Jens Juul} and Ele Ferrannini",
year = "2012",
month = aug,
doi = "10.1210/jc.2012-1205",
language = "English",
volume = "97",
pages = "2818--26",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "8",
}
RIS
TY - JOUR
T1 - Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes
AU - Muscelli, Elza
AU - Casolaro, Arturo
AU - Gastaldelli, Amalia
AU - Mari, Andrea
AU - Seghieri, Giuseppe
AU - Astiarraga, Brenno
AU - Chen, Yu
AU - Alba, Maria
AU - Holst, Jens Juul
AU - Ferrannini, Ele
PY - 2012/8
Y1 - 2012/8
N2 - Dipeptidyl peptidase IV (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes. The underlying mechanisms (incretin effect, β-cell function, endogenous glucose production) are not well known.
AB - Dipeptidyl peptidase IV (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes. The underlying mechanisms (incretin effect, β-cell function, endogenous glucose production) are not well known.
KW - Adult
KW - Aged
KW - Blood Glucose
KW - Diabetes Mellitus, Type 2
KW - Double-Blind Method
KW - Female
KW - Glucagon
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Hypoglycemic Agents
KW - Insulin-Secreting Cells
KW - Male
KW - Middle Aged
KW - Pyrazines
KW - Triazoles
U2 - 10.1210/jc.2012-1205
DO - 10.1210/jc.2012-1205
M3 - Journal article
C2 - 22685234
VL - 97
SP - 2818
EP - 2826
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 8
ER -